These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 18771751)

  • 1. Reflux inhibitors: a new approach for GERD?
    Boeckxstaens GE
    Curr Opin Pharmacol; 2008 Dec; 8(6):685-9. PubMed ID: 18771751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of gastro-esophageal reflux disease: the new kids to block.
    Blondeau K
    Neurogastroenterol Motil; 2010 Aug; 22(8):836-40. PubMed ID: 20663054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel treatments of GERD: focus on the lower esophageal sphincter.
    Lehmann A
    Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():103-10. PubMed ID: 18924449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study.
    Beaumont H; Smout A; Aanen M; Rydholm H; Lei A; Lehmann A; Ruth M; Boeckxstaens G
    Aliment Pharmacol Ther; 2009 Nov; 30(9):937-46. PubMed ID: 19650825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors.
    Johnson DA; Levy BH
    Expert Opin Pharmacother; 2010 Jun; 11(9):1541-8. PubMed ID: 20450445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GABAB receptors as drug targets to treat gastroesophageal reflux disease.
    Lehmann A
    Pharmacol Ther; 2009 Jun; 122(3):239-45. PubMed ID: 19303900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical treatment of GORD. Emerging therapeutic targets and concepts.
    Zerbib F
    Best Pract Res Clin Gastroenterol; 2010 Dec; 24(6):937-46. PubMed ID: 21126705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for gastroesophageal reflux disease.
    Boeckxstaens GE
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):481-91. PubMed ID: 19650746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and nonerosive reflux disease.
    Tack J
    Curr Opin Gastroenterol; 2005 Jul; 21(4):454-60. PubMed ID: 15930988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New pharmacological agents for the treatment of gastroesophageal reflux disease.
    Vakil N
    Rev Gastroenterol Disord; 2008; 8(2):117-22. PubMed ID: 18641594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?
    Beaumont H; Boeckxstaens GE
    Am J Gastroenterol; 2009 Jul; 104(7):1764-71. PubMed ID: 19491837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lesogaberan, a GABA(B) agonist for the potential treatment of gastroesophageal reflux disease.
    Bredenoord AJ
    IDrugs; 2009 Sep; 12(9):576-84. PubMed ID: 19697277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action.
    Lehmann A; Antonsson M; Holmberg AA; Blackshaw LA; Brändén L; Bräuner-Osborne H; Christiansen B; Dent J; Elebring T; Jacobson BM; Jensen J; Mattsson JP; Nilsson K; Oja SS; Page AJ; Saransaari P; von Unge S
    J Pharmacol Exp Ther; 2009 Nov; 331(2):504-12. PubMed ID: 19648470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological targets in gastro-oesophageal reflux disease.
    Piche T; Galmiche JP
    Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):333-41. PubMed ID: 16364047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational gastrointestinal pharmacology in the 21st century: 'the lesogaberan story'.
    Boeckxstaens GE; Denison H; Jensen JM; Lehmann A; Ruth M
    Curr Opin Pharmacol; 2011 Dec; 11(6):630-3. PubMed ID: 22036168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects.
    Boeckxstaens GE; Rydholm H; Lei A; Adler J; Ruth M
    Aliment Pharmacol Ther; 2010 Jun; 31(11):1208-17. PubMed ID: 20222915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.
    Vakil NB; Huff FJ; Cundy KC
    Aliment Pharmacol Ther; 2013 Jul; 38(2):107-17. PubMed ID: 23721547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of baclofen on oesophageal motility and transient lower oesophageal sphincter relaxations in GORD patients: a 48-h manometric study.
    Grossi L; Spezzaferro M; Sacco LF; Marzio L
    Neurogastroenterol Motil; 2008 Jul; 20(7):760-6. PubMed ID: 18373654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapies for gastroesophageal reflux disease.
    Bredenoord AJ
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):129-38. PubMed ID: 20485251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutics for gastro-esophageal reflux symptoms.
    Zerbib F; Simon M
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):533-41. PubMed ID: 23121276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.